ANN ONCOL:cabozantinib治疗甲状腺髓样癌患者总生存分析

2017-11-30 MedSci MedSci原创

之前报道的cabozantinib治疗晚期甲状腺髓样癌的临床试验结果证明其与安慰剂相比可以显着改善患者无进展生存情况。ANN ONCOL近期发表了一篇文章,报道了长期随访后总生存情况。

之前报道的cabozantinib治疗晚期甲状腺髓样癌的临床试验结果证明其与安慰剂相比可以显着改善患者无进展生存情况。ANN ONCOL近期发表了一篇文章,报道了长期随访后总生存情况。

该研究在330例转移性甲状腺髓样癌患者中比较cabozantinib和安慰剂的疗效。患者随机(2:1)分为cabozantinib(140mg/天)组或安慰剂组。平均随访时间为42个月。K-M分析表明cabozantinib平均总生存与对照组相比增加5.5个月(26个月 vs 21.1个月),尽管这一区别并无统计学意义。进一步探索性研究总生存,无进展生存和反应率后发现,cabozantinib在存在RET M918T突变的患者中取得的治疗效果更好。RET M918T阳性的患者进行cabozantinib治疗的平均总生存期为44.3个月,安慰剂治疗平均总生存期为18.9个月,而RET M918T阴性患者中这一数据为20.2个月 vs 21.5个月。cabozantinib平均治疗持续时间为10.8个月,安慰剂组为3.4个月。cabozantinib安全性与之前的分析一致。

文章最后认为,cabozantinib治疗转移性甲状腺髓样癌患者临床试验最终总生存分析并未达到研究终点。与安慰剂组对比,cabozantinib组总生存有一定改善,但无统计学差异。RET M918T阳性的患者接受cabozantinib治疗可能临床获益更大。

原始出处:
M Schlumberger,R Elisei,et al.Overall survival analysis of EXAM,a phase Ⅲ trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma.ANN ONCOL.November 2017 doi:https://doi.org/10.1093/annonc/mdx479

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1865218, encodeId=5c4b1865218b5, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Jul 30 02:18:00 CST 2018, time=2018-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822000, encodeId=452a182200043, content=<a href='/topic/show?id=26091021157a' target=_blank style='color:#2F92EE;'>#髓样癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102115, encryptionId=26091021157a, topicName=髓样癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Mon Dec 18 18:18:00 CST 2017, time=2017-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530316, encodeId=41b81530316af, content=<a href='/topic/show?id=733a395650' target=_blank style='color:#2F92EE;'>#cabozantinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3956, encryptionId=733a395650, topicName=cabozantinib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a95b12086600, createdName=zhao4620, createdTime=Sat Dec 02 07:18:00 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597988, encodeId=1d37159e98833, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Sat Dec 02 07:18:00 CST 2017, time=2017-12-02, status=1, ipAttribution=)]
    2018-07-30 minlingfeng
  2. [GetPortalCommentsPageByObjectIdResponse(id=1865218, encodeId=5c4b1865218b5, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Jul 30 02:18:00 CST 2018, time=2018-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822000, encodeId=452a182200043, content=<a href='/topic/show?id=26091021157a' target=_blank style='color:#2F92EE;'>#髓样癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102115, encryptionId=26091021157a, topicName=髓样癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Mon Dec 18 18:18:00 CST 2017, time=2017-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530316, encodeId=41b81530316af, content=<a href='/topic/show?id=733a395650' target=_blank style='color:#2F92EE;'>#cabozantinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3956, encryptionId=733a395650, topicName=cabozantinib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a95b12086600, createdName=zhao4620, createdTime=Sat Dec 02 07:18:00 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597988, encodeId=1d37159e98833, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Sat Dec 02 07:18:00 CST 2017, time=2017-12-02, status=1, ipAttribution=)]
    2017-12-18 Boyinsh
  3. [GetPortalCommentsPageByObjectIdResponse(id=1865218, encodeId=5c4b1865218b5, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Jul 30 02:18:00 CST 2018, time=2018-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822000, encodeId=452a182200043, content=<a href='/topic/show?id=26091021157a' target=_blank style='color:#2F92EE;'>#髓样癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102115, encryptionId=26091021157a, topicName=髓样癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Mon Dec 18 18:18:00 CST 2017, time=2017-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530316, encodeId=41b81530316af, content=<a href='/topic/show?id=733a395650' target=_blank style='color:#2F92EE;'>#cabozantinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3956, encryptionId=733a395650, topicName=cabozantinib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a95b12086600, createdName=zhao4620, createdTime=Sat Dec 02 07:18:00 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597988, encodeId=1d37159e98833, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Sat Dec 02 07:18:00 CST 2017, time=2017-12-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1865218, encodeId=5c4b1865218b5, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Jul 30 02:18:00 CST 2018, time=2018-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1822000, encodeId=452a182200043, content=<a href='/topic/show?id=26091021157a' target=_blank style='color:#2F92EE;'>#髓样癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102115, encryptionId=26091021157a, topicName=髓样癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Mon Dec 18 18:18:00 CST 2017, time=2017-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530316, encodeId=41b81530316af, content=<a href='/topic/show?id=733a395650' target=_blank style='color:#2F92EE;'>#cabozantinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3956, encryptionId=733a395650, topicName=cabozantinib)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a95b12086600, createdName=zhao4620, createdTime=Sat Dec 02 07:18:00 CST 2017, time=2017-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1597988, encodeId=1d37159e98833, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Sat Dec 02 07:18:00 CST 2017, time=2017-12-02, status=1, ipAttribution=)]
    2017-12-02 闆锋旦

相关资讯

JCEM:除了降钙素,它也可以评估甲状腺髓样癌预后?

众所周知降钙素是预测甲状腺髓样癌(MCT)预后的重要指标,然而由于其需要在较长时间内多次测量,使其成为了评估预后不完美的生物标记物。单循环游离DNA(cfDNA)已经显示出对多种实体肿瘤有效的预后标记物。Gilbert J. Cote等人对cfDNA在MCT中的预后评估价值进行了研究。

JAMA Surg:甲状腺髓样癌TNM分期方法研究

研究认为现行的甲状腺髓样癌TNM分期不能有效的区分患者分层风险,应采取新的患者分期方法实现准确的危险分层并优化治疗选择

Thyroid:索拉非尼治疗晚期甲状腺髓样癌有效性和安全性评价

研究者进行了一项研究,评估索拉非尼治疗晚期甲状腺髓样癌 (MTC)的有效性和安全性。该回顾性队列研究纳入了2011-12至2015-1月间的13名进展性转移的MTC患者,服用索拉非尼400 mg 两次/天。以索拉非尼治疗下的疾病缓解情况和无进展生存(PFS)作为主要结局指标。因为开始索拉非尼治疗后1周,出现严重皮肤过敏反应而排出了1名患者。12名转移性MTC患者的研究数据显示,参与者中位数年龄48

FDA批准cabozantinib用于治疗甲状腺髓样癌

       11月29日,美国食品药品监督管理局(FDA)批准了cabozantinib (Cometriq)用于治疗转移性甲状腺髓样癌,尽管该药物在临床试验中并未延长患者的总生存期。很显然,FDA对这种又名XL184的广谱激酶抑制剂在临床试验中显著的PFS(无进展生存期)益处和轻微毒性反应很满意。       &

JCEM:甲状腺髓样癌患者的骨转移和骨骼相关事件研究

癌症患者发生骨转移(BM),可能会导致严重的骨骼相关事件(SRES);目前关于甲状腺髓样癌(MTC)骨转移患者的骨骼事件数据仍缺乏。我们进行了一项研究,评估MTC患者的BM和SREs的自然发生史。 研究纳入了1991-2014年有BM和SREs相关数据的MTC患者,进行回顾性研究。 1008例MTC患者中,188例有BM(19%),其中89%(168 / 188)的患者有外远处转移。从